KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Current Assets (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Current Assets data on record, last reported at $10.6 billion in Q3 2025.

  • For Q3 2025, Current Assets changed N/A year-over-year to $10.6 billion; the TTM value through Sep 2025 reached $10.6 billion, changed N/A, while the annual FY2024 figure was $9.6 billion, 32.15% down from the prior year.
  • Current Assets reached $10.6 billion in Q3 2025 per VRTX's latest filing, up from $9.6 billion in the prior quarter.
  • Across five years, Current Assets topped out at $14.7 billion in Q3 2023 and bottomed at $8.5 billion in Q1 2021.
  • Average Current Assets over 5 years is $11.8 billion, with a median of $11.9 billion recorded in 2022.
  • Peak YoY movement for Current Assets: rose 6.87% in 2023, then plummeted 32.15% in 2024.
  • A 5-year view of Current Assets shows it stood at $8.5 billion in 2021, then surged by 54.99% to $13.2 billion in 2022, then grew by 6.87% to $14.1 billion in 2023, then tumbled by 32.15% to $9.6 billion in 2024, then grew by 10.14% to $10.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $10.6 billion in Q3 2025, $9.6 billion in Q4 2024, and $14.1 billion in Q4 2023.